Search Results

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”) announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.

Scilex Holding Company announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc..

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the shares of common stock of Scilex Holding Company that were distributed by Sorrento to its stockholders as a dividend on January 19, 2023.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.